Tg Therapeutics (TGTX) Other Non-Current Liabilities (2010 - 2026)

Tg Therapeutics' Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $777000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 64.08% year-over-year to $777000.0; the TTM figure through Mar 2026 stood at $777000.0 (down 64.08% YoY), while the FY2025 annual figure was $2.1 million, down 44.56% from the prior year.
• Other Non-Current Liabilities was $777000.0 for Q1 2026 at Tg Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.8 million in Q4 2024 to a low of $243000.0 in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $2.1 million across 5 years, with a median of $2.2 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities soared 961.62% in 2024, then slumped 64.08% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $243000.0 in 2022, then jumped by 46.91% to $357000.0 in 2023, then jumped by 961.62% to $3.8 million in 2024, then slumped by 44.56% to $2.1 million in 2025, then sank by 63.02% to $777000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $777000.0 (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.